Palatin Technologies, Inc. (“Palatin”) disclosed today that, as requested by the Food and Drug Administration (“FDA”), additional data assessing 24-hour ambulatory blood pressure with short-term daily use of Vyleesi® in
premenopausal healthy volunteers has been submitted to the FDA. The current Prescription Drug User Fee Act ("PDUFA") date for completion of FDA review of the Vyleesi New Drug Application is June 23, 2019.

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained herein or therein which do not describe historical facts, including, among others, expectations as to the FDA's requests; beliefs that the data submitted prior to the PDUFA date will be sufficient; the impact on the timeline of the potential approval of Vyleesi; and expectations as to further discussions with the FDA are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include, among others, the risk that the FDA will require additional or more comprehensive study data, or issue a complete response letter, which could cause a further delay or challenges to the approval of the Vyleesi NDA, or which could result in unanticipated restrictions or warnings on the product label, if approved, and the risk that the costs associated with such efforts will be higher than anticipated, as well as those risks identified in Palatin's filings with the U.S. Securities and Exchange Commission (the "Commission"), including its Annual Report on Form 10-K for the year ended June 30, 2018 and subsequent filings with the Commission, including its Quarterly Reports on Form 10-Q for the quarters ended September 30, 2018 and December 31, 2018, which are available at the Commission's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Palatin's results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on Palatin's stock price. Palatin cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Palatin disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PALATIN TECHNOLOGIES, INC.

Date: April 4, 2019

By: /s/ Stephen T. Wills

Stephen T. Wills, CPA, MST
Executive Vice President, Chief Financial Officer and Chief Operating Officer